BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

There have been significant advances with regard to BRAF-targeted therapies against metastatic melanoma. However, the majority of patients receiving BRAF inhibitors (BRAFi) manifest disease progression within a year. We have recently shown that melanoma patients treated with BRAFi exhibit an increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093/
https://www.ncbi.nlm.nih.gov/pubmed/24251082
http://dx.doi.org/10.4161/onci.26615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093/
https://www.ncbi.nlm.nih.gov/pubmed/24251082
http://dx.doi.org/10.4161/onci.26615

Ejemplares similares